Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19 by Delaunois, A, Abernathy, M, Anderson, WD, Beattie, KA, Chaudhary, KW, Coulot, J, Gryshkova, V, Hebeisen, S, Holbrook, M, Kramer, J, Kuryshev, Y, Leishman, D, Lushbough, I, Passini, E, Redfern, WS, Rodriguez, B, Rossman, EI, Trovato, C, Wu, C, Valentin, J